Loading
A phase 2 trial of Linvoseltamab in multiple myeloma, run by Regeneron Pharmaceuticals, active and no longer recruiting.
A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma is a phase 2 interventional study registered as NCT05955508 by Regeneron Pharmaceuticals, with 40 participants enrolled, started 2024-01-30 and due to reach its primary completion in 2033-01-25. Interventions recorded: Linvoseltamab. Conditions listed: Smoldering Multiple Myeloma (SMM). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Linvoseltamab, Smouldering multiple myeloma, Regeneron, T-cell engagers (bispecific).
Shares Linvoseltamab, Regeneron, T-cell engagers (bispecific), Multiple myeloma.
Shares Linvoseltamab, Smouldering multiple myeloma, Regeneron, T-cell engagers (bispecific).
Shares Linvoseltamab, Regeneron, T-cell engagers (bispecific), Multiple myeloma.
Shares Linvoseltamab, Regeneron, T-cell engagers (bispecific), Multiple myeloma.
Shares Linvoseltamab, Regeneron, T-cell engagers (bispecific), Multiple myeloma.
Shares Linvoseltamab, Regeneron, T-cell engagers (bispecific), Multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/